Oncoinvent ASA (CHIX:ONCINO) Marketable Securities: kr0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr11,961.53
! 5 Warning Signs
View Full Analysis

What is Oncoinvent ASA Marketable Securities?

Oncoinvent ASA CHIX:ONCINO 36 Marketable Securities is kr0.00 Mil as of Dec. 2025. GuruFocus rates CHIX:ONCINO with a GF Score™ of 36/100 and a GF Value™ of kr11,961.53. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Oncoinvent ASA's Marketable Securities for the quarter that ended in Dec. 2025 was kr0.00 Mil.

Oncoinvent ASA  (CHIX:ONCINo) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Oncoinvent ASA Marketable Securities Related Terms

Oncoinvent ASA Marketable Securities Historical Data

* Premium members only.

The historical data trend for Oncoinvent ASA's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncoinvent ASA Marketable Securities Chart

Oncoinvent ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Oncoinvent ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncoinvent ASA Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of kr0.00 Mil mean?
Oncoinvent ASA (CHIX:ONCINO) has a Marketable Securities of kr0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Marketable Securities too high?
Oncoinvent ASA's current Marketable Securities is kr0.00 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Marketable Securities compare to VRTX and REGN?
Oncoinvent ASA's Marketable Securities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Marketable Securities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Marketable Securities of kr0.00 Mil. The stock's GF Value™ is kr11,961.53, compared to a current price of kr1,039.91 — trading 91.3% below its estimated fair value. The current Marketable Securities is kr0.00 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Marketable Securities is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 91.3% below its estimated GF Value™ of kr11,961.53.

Key valuation signals for CHIX:ONCINO:

  • Marketable Securities: kr0.00 Mil
  • GF Value™: kr11,961.53 vs. price of kr1,039.91 (91.3% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr11,961.53
GF Value